Jennifer Berres - 10 Feb 2026 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Role: SVP & Chief Human Res. Officer
Signature: /s/ Kevin A. Ball, Attorney-in-Fact
Issuer symbol: HCA
Transactions as of: 10 Feb 2026
Net transactions value: -$5,389,606
Form type: 4
Filing time: 12 Feb 2026, 18:36:34 UTC
Previous filing: 02 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Berres Jennifer	SVP & Chief Human Res. Officer	ONE PARK PLAZA, NASHVILLE	/s/ Kevin A. Ball, Attorney-in-Fact	12 Feb 2026	0001793262

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCA	Common Stock	Award	$0	+7,116	+46%	$0.000000	22,528	10 Feb 2026	Direct	F1
transaction	HCA	Common Stock	Tax liability	$1,262,656	-2,515	-11%	$502.05	20,013	10 Feb 2026	Direct
transaction	HCA	Common Stock	Sale	$2,017,030	-4,010	-20%	$503.00	16,003	11 Feb 2026	Direct
transaction	HCA	Common Stock	Sale	$2,109,920	-4,010	-25%	$526.16	11,993	11 Feb 2026	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 30, 2023, the reporting person was granted 3,558 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2023-2025. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2023-2025 earnings per share, the number of performance share units that vested equaled 200% of the units granted.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.97to $526.3101, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

On January 30, 2023, the reporting person was granted 3,558 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2023-2025. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2023-2025 earnings per share, the number of performance share units that vested equaled 200% of the units granted.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.97to $526.3101, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.